Abstract. The development of side-effects during doxorubicin-docetaxel (DOX-DTX) chemotherapy is considered as related to generation of oxidative stress by DOX. The addition of docetaxel potentiates this effect. Thus, antioxidants are assumed as a promising remedy for neutralizing deteriorating effects of reactive oxygen species (ROS) in pathological conditions and polyphenolic antioxidants are suitable candidates for such a therapeutic approach.
Introduction
Doxorubicin (DOX) and docetaxel (DTX) are among the most efficient anticancer chemotherapeutics and are often used in combination, especially against advanced, refractory or metastatic breast cancer. DOX acts via numerous distinct mechanisms and pathways, including intercalation to DNA, induction of apoptosis and direct or indirect production of oxygen free radicals (Koceva-Chyła et al. 2005; Rogalska et al. 2008; Sawyer et al. 2010) . Despite the high anticancer efficiency of this anthracycline, its use is often limited due to the systemic and organ toxic effects (mainly cardiotoxicity), which can be developed many years after completion of chemotherapy (Santin et al. 2007) . So far, the main mode of the antiproliferative activity of DTX (formation of stable microtubules and induction of apoptosis) has focused the most research on this taxane (Morse et al. 2005) . More recently, the attention was shifted to the possibility of induction of ROS production by this drug (Mir et al. 2009 ).
Although the combination of DOX and DTX improves clinical outcome, the addition of taxane enhances the cardiotoxicity of DOX, mainly due to the stimulation of doxorubicinol and the intensified ROS formation in the heart myocytes (Minotti et al. 2001; Salvatorelli et al. 2006) . Thus, there is a continuous search for efficient antioxidant compounds, which could suppress the development of oxidative stress and ensure tissue protection against toxicities caused by anthracycline chemotherapy.
Flavonoids are good candidates in this field as they can scavenge different ROS, chelate metal ions and inhibit the activities of some enzymes e.g. NADPH oxidases (Mira et al. 2002; Steffen et al. 2008) . The beneficial antioxidant properties of these compounds are still appreciated and several phenolic compounds have been introduced to pre-or clinical trials, e.g. curcumin (Hatcher et al. 2008 ) and quercetin (Ferry et al. 1996; Jin et al. 2010) . Activity of flavonoids in vivo remains, however, not fully revealed, due to their poor solubility and absorption from the gastrointestinal tract and complexity of cellular action. Although flavonoids may prevent tissues and organs from oxidative injury induced by anticancer drugs in vivo, they are double-edged swords and can also act as prooxidants (Lee-Hilz et al. 2006) . Furthermore, flavonoids possess pro-apoptotic and anticancer activities and thus could enhance the cytotoxicity of anticancer drugs against tumor cells (Choi et al. 2008) .
Quercetin is an essential polyphenolic compound of a diet rich in fruit and vegetables (Slimestad et al. 2007 ). This flavonoid has been shown to protect against cancer development (Murakami et al. 2008 ) and oxidative damage generated by DOX in neonatal rat cardiomyocytes (Psotová et al. 2004) . In clinical trials i.v. infusions of quercetin did not cause substantial toxicity in humans and adverse effects were observed only for the high doses of flavonoid (Ferry et al. 1996) .
Although there are numerous studies on the activity of quercetin in in vivo and in vitro models, the possible protective effect of flavonoid against oxidative damage of blood plasma constituents by process of carcinogenesis and DOX-DTX chemotherapy has not been investigated. To the best of our knowledge our study is the very first one in this field. We employed the animal model of carcinogenesis (Sprague-Dawley rats bearing DMBA-induced mammary tumors) and measured the level of the main biomarkers of oxidative stress in the blood plasma of rats treated with: i) quercetin alone; ii) the combination of DOX and DTX without quercetin and iii) the combination of DOX and DTX with addition of quercetin.
Materials and Methods

Chemicals
Quercetin dihydrate was purchased from Carl Roth Gmbh, Germany. DTX and DOX were provided by Sequoia Research Products Ltd., United Kingdom. 2,6-di-tert-butyl-4-hydroxytoluene (BHT), 7,12-dimethylbenz(a)anthracene (DMBA), ferrous ammonium sulfate, bovine serum albumin (BSA), 2,4-dinitrophenylhydrazine (DNPH), di-thionitrobenzoic acid (DTNB), 1,1-diphenyl-2-picrylhydrazyl (DPPH), guanidine-HCl and D-sorbitol were obtained from Sigma-Aldrich. Xylenol orange and adrenaline were purchased from MP Biomedicals. Hydrogen peroxide, 2-thiobarbituric acid (TBA), trichloroacetic acid (TCA), ethylenediaminetetraacetic acid (EDTA) and sodium dodecyl sulfate (SDS) were provided by POCH, Poland. All other reagents were of the highest purity available. Deionized water was used in the preparation of all solutions (Millipore Corp.).
Animal study
Animals
The female Sprague-Dawley rats of average weight of 180 g were housed with free access to water and fed on a standard diet. The experiments were conducted accordingly to the Guide for the Care and Use of Laboratory Animals (National Academic Press, Washington, DC, Ed.7, 1996) , and to the guidelines for the Use of Experimental Animals (L358-86/609/EEC) and the Guiding Principles in the Use of Animals in Toxicology (1989) . Approval of an appropriate local ethics committee was obtained prior to experiments.
Tumor induction
Rats were randomly divided into two groups -a control (A) and an experimental (B). The experimental group received intragastrically 20 mg of DMBA in 1 ml of olive oil as described elsewhere (Barros et al. 2004) , while the control group received a vehicle only. Rats of the experimental group were examined for tumors weekly. Animals without any sign of tumor induction were removed from the subsequent experiments.
Chemotherapy
Rats of group B, which developed tumors were divided into 4 subgroups (6 animals each). The rats received investigated compounds ten weeks after tumor induction according to the following scheme:
Group 1: placebo (5% glucose, a vehicle for anticancer drugs and flavonoid). Rats of this group were marked as untreated Group 2: 10 mg quercetin Group 3: 5 mg DOX followed by 7.5 mg DTX injected one hour later Group 4: 5 mg DOX and 10 mg quercetin followed by 7.5 mg DTX one hour later The above amounts of all compounds were calculated per kg b.w., suspended in 5% glucose and administered i.p. 3 times at 3-week intervals.
DOX and DTX doses were calculated in relation to the corresponding doses used in human breast cancer therapy (Misset et al. 1999; Nabholtz 2003; Reagan-Shaw et al. 2007 ). In our previous study, the dose of 10 mg DOX/kg b.w. was applied to show protective properties of nitroxyl antioxidants on heart myocytes in vivo (Koceva-Chyla et al. 2003) .
Quercetin dose, evaluated in the pilot experiment and selected as the most optimal on the basis of general toxicity (e.g. weight loss, data not shown) is consistent with the previous data for this flavonoid in humans (Ferry et al. 1996) . It has been also shown that the combination of equal doses of DTX and DOX increased general toxicity, but did not enhance substantially alterations in cardiac function caused by DOX employed as a single drug (Platel et al. 2000) .
Preparation of plasma samples
The rats were anesthetized, and blood from femoral vein was collected on EDTA four days after the last course of chemotherapy. Plasma was separated by centrifugation at 1500 × g for 10 min and fresh samples were used for further analyses. Each sample was analyzed at least in triplicate.
Biochemical assays
Thiol groups
The total amount of thiol groups (-SH) was measured spectrophotometrically at 412 nm as described previously (Ellman 1959) . 100 μl of 10% SDS was added to an equal volume of blood plasma, mixed with 10 mM phosphate buffer (pH 8) and the absorbance was measured at 412 nm (A0) against the blank. Subsequently, 100 μl of DTNB was added and samples were incubated at 37°C for 60 min. After incubation the absorbance was measured again at 412 nm (A1). Then, A0 was subtracted from A1 and the thiol group concentration was calculated using a molar extinction coefficient of 13.6 × 10 3 M -1 ·cm -1 . Results were expressed in nanomoles of thiol groups per mg of protein.
Protein carbonyl groups
Protein carbonyl groups were measured using DNPH as described by Levine et al. (2000) . Blood plasma samples containing 1 mg of protein were mixed with 1 ml of a 10 mM DNPH in 2.5 M HCl and incubated for 1 h at room temperature, in the dark. During incubation the samples were stirred every 15 min. After incubation, 1 ml of 20% trichloroacetic acid was added, samples were left to precipitate on ice for 10 min and then centrifuged (3000 × g, 10 min, room temperature). The protein pellet after three washings with ethanol: ethyl acetate solution (1:1 ratio, v/v) was suspended in 1 ml of 6 M guanidine-HCl and incubated at 37°C for 30 min. The absorbance was read at 370 nm against blank (6 M guanidine-HCl). The carbonyl groups' content was calculated from molar absorption coefficient ε = 21 × 10 3 M -1 ·cm -1
and expressed in nanomoles per mg of protein.
Hydroperoxides
The FOX 1 method was used for determination of hydroperoxide content (Gay and Gebicki 2000) . 100 μl of blood plasma was mixed with 1 ml of working FOX 1 reagent (solution of 125 μM xylenol orange and 100 mM sorbitol in 25 mM H 2 SO 4 , prepared each time before the use by the addition of ammonium ferrous sulfate to the final 250 μM concentration), vortexed, centrifuged (20°C, 3000 × g, 10 min) and incubated at room temperature, in the dark, for 30 min. After incubation, the absorbance of supernatant was read at 560 nm against the blank. Hydroperoxide amount was calculated from a standard curve for H 2 O 2 .
Thiobarbituric acid-reactive substances (TBARS)
The amount of thiobarbituric acid-reactive substances was measured by the method described by Rice-Evans et al. (Rice-Evans et al. 1991) . Blood plasma was mixed with equal volumes of 15% (w/v) trichloroacetic acid in 0.25 M HCl and 0.37% (w/v) 2-thiobarbituric acid in 0.25 M HCl, containing 2% BHT, and incubated at 100°C for 10 min. After then, the samples were cooled on ice and centrifuged (3000 × g, 5 min, 20°C). The supernatant was collected and its absorbance measured at 535 nm against the blank. TBARS content was calculated from E = 1.56 × 10 5 M -1 ·cm -1 and expressed in nanomoles of TBARS per milligram of protein.
SOD activity
The indirect adrenaline assay based on the measurement of inhibition of adrenaline autooxidation at 480 nm was used to calculate SOD activity (Misra and Fridovich 1972) . The plasma sample which caused 50% inhibition of adrenaline autooxidation was regarded as containing one unit of SOD.
The enzyme activity was expressed in international units per milligram of protein.
Plasma non-enzymatic antioxidant capacity (NEAC)
The estimation of the non enzymatic antioxidant capacity of the blood plasma was performed using 1,1-diphenyl-2-picrylhydrazyl (DPPH) reduction assay according to Yamaguchi et al. (1998) with some modifications. 20 μl of blood plasma was mixed with 400 μl of a 0.1 mM methanol solution of DPPH. Following 30 min incubation at room temperature and centrifugation (10 min, 3000 × g) the absorbance was measured at 517 nm. The antioxidant capacity of the plasma was expressed in nmol Trolox equivalents per mg of protein.
Assessment of protein content
The protein concentration in each sample was measured by the Lowry method from the standard curve for BSA (Lowry 1951) .
Statistical Analysis
Shapiro-Wilk's test was used to evaluate the normal distribution of data. Homogeneity of variance was evaluated by the Levene's test. Student's t-test was applied in order to estimate the statistical significance between the groups (Table 1) . The parametric, two-way analysis of variance was used to test any possible interactions between compounds (DOX-DTX and quercetin). The two-way nested analysis of variance was used in the case of interactions, assuming that the effect of drugs is at a higher level of importance than the effect of quercetin (Sokal and Rohlf 1994; Zar 1999) . Differences were considered significant at p < 0.05.
The Statistica (StatSoft Inc., Tulsa, OK, USA) and StatsDirect (StatsDirect Ltd., England) software was used for all calculations.
Results
Changes in the blood plasma of untreated tumor-bearing rats
Alterations in the amount of analyzed biomarkers of oxidative stress in the blood plasma of healthy (control) and tumor-bearing rats (untreated) provided in Table 1 imply that the process of DMBA-carcinogenesis generates significant oxidative stress in the tumor-bearing rats. This is evidenced by an increase in protein carbonyls and lipid peroxidation products (hydroperoxides and TBARS) and a decrease in SOD activity. Additionally, an increase in the non-enzymatic antioxidant capacity (NEAC) and thiol groups has also been observed.
The effect of quercetin
Administration of quercetin caused a decrease of lipid peroxidation products (TBARS and hydroperoxides) in the blood plasma of tumor-bearing rats but did not influence protein carbonyl groups and SOD activity. The flavonoid also reduced the content of thiol groups to the level of the control animals and evoked an increase of the NEAC (Table 1) .
The impact of quercetin on the oxidative stress generated by DOX and DTX
The inclusion of quercetin into DOX-DTX chemotherapy effectively protected the blood plasma constituents against oxidative damage induced by these drugs and resulted in a decrease in lipid peroxidation end products (TBARS) and protein carbonyl groups. Moreover, the addition of flavonoid increased the amount of thiols, non-enzymatic plasma antioxidant capacity (NEAC) and SOD activity but also the level of hydroperoxides (Figure 1 ). Quercetin had the positive effect on the outcome of chemotherapy as greater reduction in tumor size was observed in rats treated with 11.94 ± 0.752 ## Data were expressed as mean ± SD. Control, healthy rats; Untreated, rats with tumors receiving placebo only (5% glucose); Quercetin, quercetin-treated rats; DMBA, -7,12-dimethylbenz(a)anthracene; NEAC, non-enzymatic antioxidant capacity; SOD, superoxide dismutase; TBARS, thiobarbituric acid-reactive substances. ** p < 0.001, *** p < 0.0001 -vs. healthy rats; ## p < 0.002, ### p < 0.0001-vs. untreated rats; n.s., non significant.
DOX-DTX chemotherapy with the addition of flavonoid (data not shown).
Discussion
Anticancer drugs induce extensive oxidative stress in both normal and tumor cells. Electrophilic aldehydes, which are end products of lipid peroxidation cause perturbation in the cell cycle progression and arrest of cells in the cycle checkpoints (Ji et al. 1998; Chua et al. 2009 ). In cancer cells this effect may hamper the anticancer activity of chemotherapeutics and lessen the efficacy of the treatment. Oxidative damage of lipids, proteins and DNA in normal cells can in turn destroy the functions of many tissues, which leads to severe side effects of chemotherapy employing drugs that generate oxidative stress. Moreover, products of lipid peroxidation can also inhibit drug-induced apoptosis through inactivating death receptors and caspase activity (Camandola et al. 2000; Leonarduzzi et al. 2000; Liu et al. 2000; Yang et al. 2003) . Thus, the use of antioxidants may enhance the efficacy of chemotherapy and reduce its undesirable nontargeted effects by ameliorating the generation of oxidative stress-induced harmful products, e.g. aldehydes.
Oxidative stress is also inevitably associated with the process of carcinogenesis (Barrera 2012) . In untreated tumor-bearing rats we have observed a considerable increase in the level of carbonyl groups, hydroperoxides and TBARS, coupled with a decrease in SOD activity and an increase in thiols and NEAC. This indicates the existence of extensive oxidative stress, linked to the process of DMBA-carcinogenesis and tumor development which is in line with other Figure. 1. The effect of quercetin (Q) on the oxidative stress generated by combination of anticancer drugs doxorubicin (DOX) and docetaxel (DTX) in the blood plasma of rats with experimental mammary cancer. Data were expressed as mean ± SD. * p < 0.05 denotes a statistically significant difference in relation to untreated rats, # p < 0.05 DOX-DTX vs. DOX-DTX+Q.
papers showing the significance of oxidative stress in these processes (Kumaraguruparan et al. 2002; Klaunig et al. 2011) .
In tumor-bearing rats treated with quercetin a significant decrease in TBARS and hydroperoxides suggests protective effect of flavonoid on peroxidation of the blood plasma lipids. This is in accordance with the earlier report showing a reduction in lipid peroxidation products in the plasma of rats treated with this flavonoid (da Silva et al. 1998) . At the same time we did not observe any impact of quercetin on the level of protein carbonylation. Similar effect of flavonoid has been observed by Ameho et al. (2008) in the vitamin Edepleted rats administered with this flavonoid.
Administration of quercetin did not cause any changes in SOD activity. Conversely to our results an increase in SOD activity in mice receiving quercetin has been reported (Kamaraj et al. 2007 ). It should be mentioned that in these experiments much higher doses of flavonoid were applied (25 mg/kg body weight, twice a week for 16 weeks) which could exert other effect on SOD activity. In addition, quercetin has been shown to suppress activation of pro-inflammatory NF-κB via reducing ROS level (Nam et al. 2006) . Flavonoid could also decrease the level of pro-inflammatory tumor necrosis factor (TNF-α) in blood plasma of mice (Boesch-Saadatmandi et al. 2011 ) and thus protect against oxidative stress mediated by this cytokine. Other studies indicate that quercetin empowers the endogenous antioxidant system due to upregulation of the antioxidant enzyme activity (Kamaraj et al. 2007; Bournival et al. 2012; Huang et al. 2012) . Moreover, it has been also suggested that flavonoids might act synergistically with the endogenous antioxidant system and thus decrease oxidative stress (Chen et al. 2005) .
In our experimental setting quercetin also caused augmentation of NEAC in tumor-bearing rats. This suggests the ability of low molecular weight antioxidants of blood plasma to sustain its proper redox state in conditions of oxidative stress. Recently, quercetin has been shown to increase the level of heme oxygenase 1 protein (HO-1), probably via an Nrf2-dependent pathway (Boesch-Saadatmandi et al. 2011) , which consecutively may increase the level of bilirubin (Zelenka et al. 2012 ). This mechanism somewhat could also contribute to a rise of NEAC observed in our study. In turn, the reduction of thiols in the tumor-bearing rats to the level of control animals might be due to the formation of quercetin conjugates with -SH groups as it has been suggested by other authors (Jacobs et al. 2010) .
We examined antioxidant properties of quercetin and its protective effects on the damage to the blood plasma constituents by oxidative stress generated by DOX-DTX chemotherapy. So far, this aspect of quercetin activity has not been investigated in vivo. Different studies report on the ability of antineoplastic agents to generate ROS in biological systems (Minotti et al. 2001; Mir et al. 2009; Sawyer et al. 2010) . Thus, the abrogation of chemotherapy-related damage by redox modulation with the use of quercetin, might have potential beneficial therapeutic implications. It should be mentioned that new clinical trials with employment of this flavonoid have been running for the last two years: A phase 1 study of quercetin in patients with Hepatitis C (National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, University of California, Los Angeles); and Clinical trial on the effectiveness of the flavonoids genistein and quercetin in men with rising prostate-specific antigen (Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany; University of Hohenheim).
Addition of quercetin to DOX-DTX chemotherapy in our study had positive impact on the plasma proteins and effectively shielded plasma lipids against oxidative destruction caused by DOX and DTX treatment. A decreased level of protein carbonylation and the end products of lipid peroxidation in plasma of rats receiving combination of drugs with quercetin was observed in comparison to the treatment with the anticancer drugs only. Several in vitro and in vivo reports describe quercetin ability to protect lipids against peroxidation (da Silva et al. 1998; Mahesh and Menon 2004; Gargouri et al. 2011 ). This effect of flavonoid could be related to its iron-chelation properties. Some evidence points out that accessibility of iron is a key factor in oxygen radical-mediated lipid peroxidation (Fischer et al. 2002) .
In contrast to the attenuation of the TBARS production, the inclusion of quercetin into DOX and DTX treatment enhanced hydroperoxide production, which could suggest prooxidant activity of flavonoid. Other authors showed that under specific conditions quercetin may exhibit prooxidant activity by increasing hydroperoxide production (Rolewski et al. 2009 ). It should be mentioned that hydroperoxides, in contrast to TBARS, are unstable products of the earlier stages of lipid peroxidation and may be successfully restored. Thus, we consider the arrest of lipid peroxidation in its earlier stages as a protective effect of quercetin, which on one side causes an increase in hydroperoxides but on the other side leads to a decrease in the amount of the most harmful and irreversible end-products of lipid peroxidation such as aldehydes. Effective protection of plasma constituents against DOX-DTX chemotherapy-induced oxidative damage confirms antioxidative properties of quercetin in vivo and is in line with reports showing the preventive role of this flavonoid against oxidation of erythrocyte and lymphocyte proteins (Pandey and Rizvi 2010; Gargouri et al. 2011) .
Summarizing, our investigation shows that quercetin is able to protect proteins and lipids of blood plasma of tumorbearing rats against oxidative damage caused by combined DOX-DTX chemotherapy and shield nontargeted tissue against toxicity of these anticancer drugs.
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